Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.45 |
| ▸ | CCND1 | P24385 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17646130 | 0.82 | CDK4 (0.40) | CDK4CCND1NOTUMSLC6A2OPRM1 | |
| SCHEMBL30991314 | 0.80 | CDK4 (0.45) | CDK4CCND1NOTUMSLC6A2HTR2A | |
| SCHEMBL13183721 | 0.79 | SLC6A2 (0.43) | CDK4CCND1NOTUMSLC6A2HTR2A | |
| SCHEMBL321199 | 0.77 | CDK4 (0.45) | CDK4CCND1NOTUMSLC6A2HTR2A | |
| SCHEMBL29614841 | 0.77 | CDK4 (0.45) | CDK4CCND1NOTUMSLC6A2HTR2A | |
| Hydrochloric Acid SCHEMBL7218572 | 0.75 | CDK4 (0.43) | CDK4CCND1NOTUMSLC6A2HTR2A | |
| SCHEMBL4952843 | 0.74 | HTR2C (0.38) | HTR2AHTR2CCYP1A2CA12CA9 | |
| SCHEMBL4955692 | 0.74 | PRKCI (0.44) | HTR2AHTR2CCYP3A4BRPF1ALDH1A1 | |
| SCHEMBL4630982 | 0.74 | NOTUM (0.44) | NOTUMCYP1A2CYP3A4MAPK1CYP2C19 | |
| SCHEMBL3576716 | 0.73 | CDK4 (0.47) | CDK4CCND1NOTUMSLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2005075426-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005066157-A1 | 3-(PYROLIDIN-3-L) INDOLES AS 5-HT6 RECEPTOR MODULATORS | SUVEN LIFE SCIENCES (IN) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | CDK4 119/4885CCND1 837/4885NOTUM 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.